Friday September 3rd
 
 
 


UNITED STATES - 116 news UNITED KINGDOM - 18 news AUSTRALIA - 14 news SWEDEN - 10 news JAPAN - 9 news CANADA - 8 news IRELAND - 8 news GERMANY - 7 news SWITZERLAND - 6 news DENMARK - 6 news FRANCE - 5 news NORWAY - 5 news ISRAEL - 4 news NETHERLANDS - 3 news INDIA - 1 news Most active countries (last 30 days) [enlarge]

 

  Next
[ 31 ]
[ 26 ]
[ 21 ]
[ 19 ]
[ 17 ]
[ 17 ]
[ 17 ]
[ 16 ]
[ 14 ]
[ 14 ]
[ 13 ]
[ 13 ]
[ 12 ]
[ 12 ]
[ 12 ]
[ 12 ]
[ 12 ]
[ 11 ]
[ 11 ]
[ 11 ]
Most active sources (last 90 days)
 
Jonathan Kearsey Ph.D, Director of Pharmacology & Business Development, about L2D (Leads to Development) Services' non-clinical development solutions
Jonathan Kearsey Ph.D, Director of Pharmacology & Business Development, L2D Services
[Interview]
 

::: Bausch + Lomb Names Michael J. Rowe as Corporate Vice President, Human Resources
Human Resources, Lomb Names Michael, Disney Consumer Products, Disney Publishing, Disney Store, Disney Interactive, growing high-performance global teams, global staff functions, medical transportation service company MedTrans, division of The Walt Disney Co
::: Stentys appoints Stanislas Piot as Chief Financial Officer
Stentys stents, treatment of Acute Myocardial Infarction, treat Acute Myocardial Infarction, innovative stents, revolutionary self-apposing stents, appointment of Stanislas Piot, Chief Financial Officer, Crédit Agricole Private Equity, Crédit Lyonnais Hong Kong Branch, conventional coronary stent
::: First clinical study started with BAN2401, a novel antibody targeting the neurotoxin believed to cause Alzheimer's disease
disease research, stop disease progression, devastating neurodegenerative disease, Antibody BAN2401, toxic elements of the disease, treatment of Alzheimer, Alzheimer biomarkers, moderate forms of the disease, result of Alzheimer, first monoclonal antibody
::: Grifols Obtains FDA Approval for Flebogamma® DIF 10 % IVIG
Grifols facilities, Grifols production capabilities, Grifols plans, name Flebogamma, new Flebogamma, confidence of the Grifols name, DIF 5%, DIF 10%, DIF 10 %, new IVIG production facility
::: Dr Kevin Johnson Joins Index Ventures as a Partner in the Life Sciences Team
Index Ventures team, Index Ventures Life Sciences team, Index Ventures Partner, Index Ventures portfolio, Index Life Sciences team, Partners of Index Ventures, Index Forum, Dr Kevin Johnson, Dr Johnson, asset centric model

search powered by PERTIMM: 'the discover engine'